We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




High Blood Sugar Associated with Lower Risk of Benign Tumors

By LabMedica International staff writers
Posted on 07 Jul 2016
Meningioma, is a primary tumor arising from the membrane surrounding the brain and spinal cord, accounts for more than one-third of all primary brain and central nervous system tumors.

The discovery that benign brain tumors that have previously been tied to obesity and diabetes are less likely to emerge in those with high blood sugar and this could shed light on the development of meningiomas, that are usually not cancerous but that can require risky surgery and affect a patient's quality of life.

Scientists at Ohio State University (Columbus, OH, USA) and their Swedish colleagues conducted a cohort study to evaluate the potential effects of obesity-related prediagnostic glucose, triglycerides and cholesterol on meningioma and of prediagnostic meningioma on these biomarkers. More...
They identified 41,355 individuals in the Apolipoprotein MOrtality RISk cohort with values for these biomarkers within 15 years before meningioma diagnosis, death, migration or the end of follow-up.

Meningioma was diagnosed in 181 women and 115 men whose median follow-up time was seven years. Fasting serum glucose level was inversely related to meningioma among women, but not men. Women with the highest fasting blood sugar were less than half as likely as those with the lowest readings to develop a tumor. When they compared the less-reliable non-fasting sugar readings, those taken without a period of no food or drink that could influence the results, they found that both men and women with high blood sugar had a lower likelihood of meningioma diagnosis.

The authors concluded paradoxically, hyperglycemia is inversely associated with meningioma in women. This finding does not necessarily negate the positive role of obesity or diabetes in meningioma development; rather, it may indicate that their effects depend on the stage of development. Furthermore, the prediagnostic tumor may reduce serum cholesterol levels.

Judith Schwartzbaum, PhD, a professor and the lead author of the study, said, “It's so unexpected. Usually diabetes and high blood sugar raises the risk of cancer, and it's the opposite here. These tumors take years to develop, and an earlier diagnosis would certainly lead to better surgical outcomes. It's also possible that sugar levels dip during early tumor development because the tumor is using glucose to grow.” The study was published on June 2, 2016, in the British Journal of Cancer.

Related Links:
Ohio State University


Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Blood Ammonia Test Analyzer
DRI-CHEM NX10N
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.